XML 65 R46.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Collaborative and Other Relationships (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Co-promotion profit sharing formula | As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:
After LUNSUMIO Approval until the First Threshold Date | 37.5 | %
After First Threshold Date until the Second Threshold Date | 35.0 | %
After Second Threshold Date | 30.0 | %
Pretax profit sharing formula | Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below:
Until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
Summary of activity related to the UCB collaboration | A summary of development expense related to the UCB collaboration agreement is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2024 |  | 2023 |  |  |  |
Total UCB collaboration development expense |  | $ | 16.6 |  |  | $ | 18.3 |  |  |  |  |
Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  | 8.3 |  |  | 9.2 |  |  |  |  |
Summary of Activity Related to Denali Therapeutics Collaboration | A summary of development expense related to the Denali collaboration is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2024 |  | 2023 |  |  |  |
Total Denali collaboration development expense |  | $ | 14.2 |  |  | $ | 16.6 |  |  |  |  |
Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  | 8.5 |  |  | 10.0 |  |  |  |  |
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration |
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2024 |  | 2023 |  |  |  |
Total development expense incurred by the collaboration related to the advancement of LEQEMBI |  | $ | 87.3 |  |  | $ | 107.9 |  |  |  |  |
Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  | 43.6 |  |  | 54.0 |  |  |  |  |
Total sales and marketing expense incurred by the LEQEMBI Collaboration |  | 173.9 |  |  | 10.5 |  |  |  |  |
Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income |  | 86.9 |  |  | 5.3 |  |  |  |  |
Summary of Activity Related to Sage Therapeutics | A summary of development and sales and marketing expense related to the Sage collaboration is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2024 |  | 2023 |  |  |  |
Total Sage collaboration development expense |  | $ | 11.6 |  |  | $ | 34.8 |  |  |  |  |
Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  | 5.8 |  |  | 17.4 |  |  |  |  |
Total sales and marketing expense incurred by the Sage collaboration |  | 27.6 |  |  | 38.2 |  |  |  |  |
Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income |  | 13.8 |  |  | 19.1 |  |  |  |  |

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pretax Profit Sharing Formula [Table Text Block] + References No definition available. + Details
Name: | biib_PretaxProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to Denali Therapeutics Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to Sage Therapeutics + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to the UCB Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration